Pro-Dex, Inc. (NASDAQ:PDEX - Get Free Report) Director Raymond E. Cabillot sold 836 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $50.00, for a total transaction of $41,800.00. Following the transaction, the director now directly owns 278,109 shares of the company's stock, valued at $13,905,450. This represents a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Pro-Dex Stock Performance
PDEX opened at $49.58 on Tuesday. The business's 50-day simple moving average is $40.31 and its 200 day simple moving average is $40.26. Pro-Dex, Inc. has a 52-week low of $16.84 and a 52-week high of $59.60. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.44 and a current ratio of 2.58. The firm has a market capitalization of $161.68 million, a PE ratio of 24.67 and a beta of 0.68.
Pro-Dex (NASDAQ:PDEX - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a return on equity of 21.68% and a net margin of 11.06%. As a group, sell-side analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current fiscal year.
Institutional Trading of Pro-Dex
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. EAM Investors LLC bought a new stake in shares of Pro-Dex in the 4th quarter valued at about $1,047,000. O Shaughnessy Asset Management LLC acquired a new position in Pro-Dex during the fourth quarter worth approximately $995,000. 683 Capital Management LLC acquired a new position in Pro-Dex during the fourth quarter worth approximately $739,000. Ritholtz Wealth Management acquired a new stake in shares of Pro-Dex in the fourth quarter valued at approximately $572,000. Finally, American Century Companies Inc. acquired a new stake in shares of Pro-Dex in the fourth quarter valued at approximately $558,000. 15.28% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Separately, StockNews.com cut shares of Pro-Dex from a "buy" rating to a "hold" rating in a report on Wednesday, March 12th.
Read Our Latest Report on Pro-Dex
About Pro-Dex
(
Get Free Report)
Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
